Key Facts
- Class Period
- Aug. 1, 2025 – May 15, 2026
- Lead Plaintiff Deadline
- Sept. 14, 2026
- Market Cap Wipeout
- $11 billion
- Trial Result
- Did not reach statistical significance for PFS
- Trial Therapy
- Fianlimab + Libtayo for melanoma
- Filing Firm
- Hagens Berman Sobol Shapiro LLP
Background
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals (NASDAQ: REGN) following the failure of a Phase 3 clinical trial for a melanoma therapy. The lawsuit seeks to represent investors who purchased Regeneron common stock between August 1, 2025, and May 15, 2026.
The trial tested Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma. The primary endpoint was progression-free survival (PFS), and Regeneron had described the combination as a 'potential blockbuster.'
The complaint alleges that Regeneron made false and misleading statements and failed to disclose critical information. Specifically, it claims the company did not inform investors that the trial's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achieving the primary endpoint was unlikely.
Current Situation
The truth began to emerge on April 29, 2026, when Regeneron revealed it had altered the trial protocol so that the primary analysis of PFS would consider all patients with a minimum follow-up of 6 months. An analyst questioned whether this was because the underlying PFS benefit might be insufficient to show statistical significance.
On May 12, 2026, Regeneron admitted the protocol change was made in response to 'slow event rates,' occurred nearly six months earlier, and was submitted to global regulatory authorities in November or December. Three days later, on May 15, 2026, Regeneron reported that the trial did not reach statistical significance for the primary endpoint.
The news drove Regeneron shares sharply lower, causing an $11 billion market cap wipeout. Hagens Berman Sobol Shapiro LLP is investigating the legal claims and urges investors with substantial losses to submit their losses. The lead plaintiff deadline is September 14, 2026.
| Date | Event |
|---|---|
| Aug. 1, 2025 | Class period begins |
| Nov/Dec 2025 | Protocol change submitted to regulators |
| Apr. 29, 2026 | Regeneron reveals protocol change |
| May 12, 2026 | Regeneron admits slow event rates |
| May 15, 2026 | Trial fails primary endpoint |
| Sept. 14, 2026 | Lead plaintiff deadline |
Impacts
Investors who purchased Regeneron shares during the class period may be eligible to participate in the lawsuit. Those with substantial losses have the opportunity to lead the class action, which could influence the direction of the litigation.
The lawsuit could also affect Regeneron's reputation and future clinical trial disclosures. If the allegations are proven, the company may face financial penalties and increased scrutiny from regulators and investors.
Whistleblowers with non-public information about Regeneron may be eligible for rewards under the SEC Whistleblower program, which offers up to 30 percent of successful recoveries. This could encourage more transparency in the pharmaceutical industry.
Future Outlook
Scenario analysis: The possibilities below are not certain predictions.
If the court certifies the class and the plaintiffs succeed, Regeneron could be required to compensate affected investors. The outcome may depend on whether the company's protocol changes were intentionally misleading, as alleged.
If Regeneron defends successfully, it may avoid liability, but the trial failure could still impact its pipeline and stock performance. The company may need to reassess its melanoma treatment strategy.
The case could also set a precedent for how clinical trial disclosures are handled, potentially leading to stricter regulatory requirements. However, the final resolution remains uncertain and may take years to conclude.
Source: prnewswire.com
